Implications of Myocardial Reperfusion on Survival in Women Versus Men With Acute Myocardial Infarction Undergoing Primary Coronary Intervention
In conclusion, impaired myocardial perfusion following PCI for AMI, indicated by worse MBG, is an independent predictor of early and late mortality in women but not in men. These findings imply an enhanced survival benefit from restoring myocardial perfusion for women compared with men during primary angioplasty and may have clinical implications for interventional strategies in women. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - July 8, 2013 Category: Cardiology Authors: Stephanie M. Meller, Alexandra J. Lansky, Ricardo A. Costa, Morgan Soffler, Costantino O. Costantini, Bruce R. Brodie, David A. Cox, Thomas D. Stuckey, Martin Fahy, Cindy L. Grines, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy
Abstract: Introduction: Current guidelines still recommend the bolus and infusion administration of glycoprotein IIbIIIa inhibitors in patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention. We sought to evaluate the extent of platelet inhibition by a blocking and bridging strategy with intracoronary abciximab bolus-only administration and oral loading of adenosine diphosphate receptor antagonists.Patients and methods: Fifty-six consecutive high-risk acute coronary syndrome patients with bolus-only abciximab administration (0.25mg/kg i.c.) and loading with 600mg clopidogrel (55%) or 6...
Source: Thrombosis Research - June 21, 2013 Category: Hematology Authors: Günter Christ, Thomas Hafner, Jolanta M. Siller-Matula, Marcel Francesconi, Katharina Grohs, Eva Wilhelm, Andrea Podczeck-Schweighofer Tags: Platelets and Cell Biology Source Type: research
Thromboelastometric Maximum Clot Firmness in Platelet-Free Plasma Is Influenced by the Assay Used.
CONCLUSIONS:We speculate that FIBTEM and FIBTEM PLUS may contain stabilizing agents that enhance fibrin polymerization whereas FFTEG might contain less tissue factor than the ROTEM assays.
PMID: 23733839 [PubMed - as supplied by publisher] (Source: Anesthesia and Analgesia)
Source: Anesthesia and Analgesia - June 3, 2013 Category: Anesthesiology Authors: Schlimp CJ, Solomon C, Hochleitner G, Zipperle J, Redl H, Schöchl H Tags: Anesth Analg Source Type: research
What accounts for the higher clinical efficacy of intracoronary abciximab?
We truly appreciate the interesting comment by Dominguez-Rodriguez et al. , in relation to our recently published meta-analysis comparing intracoronary and intravenous abciximab administration in patients with acute coronary syndrome , where they suggest local anti-inflammatory properties as an additional potential mechanism to explain the advantage observed with intracoronary abciximab administration . (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Salvatore De Rosa, Gianluca Caiazzo, Daniele Torella, Ciro Indolfi Tags: Letters to the Editor Source Type: research
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction
Scandinavian Cardiovascular Journal, Volume 0, Issue 0, Page 1-6, Early Online. (Source: Scandinavian Cardiovascular Journal)
Source: Scandinavian Cardiovascular Journal - May 23, 2013 Category: Cardiology Tags: article Source Type: research
Reply
We thank Drs. Iancu and Ober for their interest in our work . We agree that timing of glycoprotein IIb/IIIa inhibitor administration is an important factor. A recent meta-analysis comparing intravenous versus intracoronary abciximab application found a trend toward a greater efficacy with intracoronary abciximab with an ischemic time (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - May 22, 2013 Category: Cardiology Authors: Ingo Eitel, Steffen Desch, Holger Thiele Tags: Letters to the Editor Source Type: research
Intracoronary Glycoprotein IIb/IIIa Inhibitors Downstream of the Coronary Occlusion: The “Highway” to Periphery
We read with interest the study of Eitel et al. about the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-Elevation Myocardial Infarction) trial, regarding infarct size. The study shows an interesting result: Microvascular Obstruction (MO) and infarct size did not significantly differ between intravenous versus intracoronary administration of abciximab. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - May 22, 2013 Category: Cardiology Authors: Adrian C. Iancu, Camelia Ober Tags: Letters to the Editor Source Type: research
P2Y12 Receptor Blockade Augments Glycoprotein IIb-IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [Coronary Heart Disease]
Conclusions
The complementary effects of abciximab and R-138727 on platelet activation, aggregation, and procoagulant activity suggest their combined use may, to a greater degree than with either agent alone, reduce thrombus formation in vivo. (Source: JAHA:Journal of the American Heart Association)
Source: JAHA:Journal of the American Heart Association - May 15, 2013 Category: Cardiology Authors: Berny-Lang, M. A., Jakubowski, J. A., Sugidachi, A., Barnard, M. R., Michelson, A. D., Frelinger, A. L. Tags: Coronary Heart Disease Source Type: research
Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
(Source: Cardiovascular and Hematological Agents in Medicinal Chemistry)
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - May 11, 2013 Category: Cardiology Authors: Rognoni, AndreaLupi, AlessadroCavallino, ChiaraRosso, RobertaVeia, AlessiaBacchini, SaraBongo, Angelo Sante Tags: Articles Source Type: research
PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty
This study showed that Leu33Pro polymorphism of Gp IIIa does not affect the extent of inhibition of platelet aggregation by Gp IIb-IIIa inhibitors. (Source: Blood Coagulation and Fibrinolysis)
Source: Blood Coagulation and Fibrinolysis - May 10, 2013 Category: Hematology Tags: Original Articles Source Type: research
Response letter to “Quality of evidence for multivariate analysis to keep stable estimates”
We thank doctor Kawada for his interesting observations. However, it must be remarked that some methodological problems were clearly recognized in our paper. In the study limitations we reported that our sample size was relatively small and although we found no differences in the rates of death, myocardial infarction in patients treated with or without abciximab during rescue angioplasty after a clopidogrel loading dose of 300mg, the study was not sufficiently powered to show differences in these clinical events . (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - May 6, 2013 Category: Cardiology Authors: Francesco De Felice, Antonio Parma, Rosario Fiorilli, Carmine Musto, Roberto Violini Tags: Letters to the Editor Source Type: research
Quality of evidence for multivariate analysis to keep stable estimates
De Felice et al. reported clinical outcome in patients treated with abciximab . I have some concern on their study outcome from a statistical viewpoint. First, they detected 35 patients with major adverse cardiac events for 30days (15 patients without abciximab and 20 patients with abciximab). Until 1year, they detected 52 patients with major adverse cardiac events (23 patients without abciximab and 29 patients with abciximab). The number of patients over 400 is required for keeping the quality of clinical evidence , although the value meets the statistical criteria. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - May 3, 2013 Category: Cardiology Authors: Tomoyuki Kawada Tags: Letters to the Editor Source Type: research
Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial
This study aimed to compare infarct size and clinical outcomes in patients with proximal versus mid left anterior descending (mLAD) infarction.Background: The extent of myocardium at risk is an important prognostic determinate in patients with ST-segment elevation myocardial infarction.Methods: The INFUSE-AMI trial randomized patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation to intracoronary (IC) bolus abciximab versus no abciximab and to thrombus aspiration versus no aspiration. The primary end point was magnetic resonan...
Source: American Heart Journal - May 2, 2013 Category: Cardiology Authors: Sorin J. Brener, Bernhard Witzenbichler, Akiko Maehara, Joe Dizon, Martin Fahy, Magdi El-Omar, Jan-Henk Dambrink, Philippe Genereux, Roxana Mehran, Keith Oldroyd, Helen Parise, C. Michael Gibson, Gregg W. Stone Tags: Acute Ischemic Heart Disease Source Type: research
Intracoronary abciximab in STEMI using local drug delivery catheter - Single center experience.
CONCLUSION: Super selective intracoronary abciximab using local drug delivery catheter during primary PCI in STEMI patients significantly improves TMP grading without increased risk of bleeding. This benefit is achieved even in patients without thrombus aspiration. We need to assess the long-term outcomes in the form of reduction in infarct size using this strategy in large group of patients.
PMID: 23809377 [PubMed - in process] (Source: Indian Heart J)
Source: Indian Heart J - May 1, 2013 Category: Cardiology Authors: Sengottuvelu G, Ravi Sekar V Tags: Indian Heart J Source Type: research
Intracoronary abciximab and local anti-inflammatory effects
We have read with great interest the article by De Rosa et al., in relation to a meta-analysis of clinical trials on the use of intracoronary abciximab . In our opinion, the author's state in the discussion only one possible potential mechanism by which the intracoronary abciximab obtains better results compared to intravenously, a higher degree of GP IIb/IIIa receptor occupancy and a more pronounced platelet inhibition. We would like to point out another possible mechanism that can account for the potential clinical benefits observed in patients receiving intracoronary abciximab, the local anti-inflammatory properties. (S...
Source: International Journal of Cardiology - April 22, 2013 Category: Cardiology Authors: Alberto Dominguez-Rodriguez, Pablo Avanzas, Pedro Abreu-Gonzalez Tags: Letters to the Editor Source Type: research
